Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers

被引:38
作者
Hammer-Wilson, MJ
Akian, L
Espinoza, J
Kimel, S
Berns, MW [1 ]
机构
[1] Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92616 USA
[2] Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel
关键词
5-aminolevulinic acid (ALA); benzoporphyrin derivative monoacid ring A (BPD-MA); lutetium texaphyrin (Lutex); photodynamic therapy; Photofrin; sulfonated chloro-aluminum phthalocyanine (AlPcSn); vascular damage;
D O I
10.1016/S1011-1344(99)00124-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The relative efficacy of Photofrin(R)-based photodynamic therapy (PDT) has been compared with that of the second-generation photosensitizers 5-aminolevulinic acid (ALA), sulfonated chloro-aluminum phthalocyanine (AlPcSn), benzoporphyrin derivative monoacid ring A (BPD-MA), and lutetium texaphyrin (Lutex). PDT-induced vascular damage in the chick chorioallantoic membrane (CAM) is measured following topical application of the photosensitizers. In order to make meaningful comparisons, carl is taken to keep treatment variables the same. These include light dose (5 and 10 J/cm(2)), power density (33 and 100 mW/cm(2)), and drug uptake time (30 and 90 min). The drug dose ranges from 0.1 mu g/cm(2) for BPD to 5000 mu g/cm(2) for ALA. Results are also analyzed statistically according to CAM vessel type (arterioles versus venules), vessel diameter, and vessel development (embryonic age). For each photosensitizer, the order of importance for the various PDT parameters is found to be unique. The differences between the sensitizers are most likely due to variation in biophysical and biochemical characteristics, biodistribution, and uptake kinetics. (C)1999 Elsevier Science S.A. All rights reserved.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 70 条
[61]  
2-8
[62]  
STERN SJ, 1991, LARYNGOSCOPE, V101, P1219
[63]  
Trauner KB, 1998, PHOTOCHEM PHOTOBIOL, V67, P133
[64]   Experimental study of combined hyperthermic and photodynamic therapy on carcinoma in the mouse [J].
Uehara, M ;
Inokuchi, T ;
Sano, K .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 1996, 54 (06) :729-736
[65]  
WINKELMAN JW, 1990, PHOTODYNAMIC THERAPY, V2, P29
[66]  
Woodburn K W, 1996, J Clin Laser Med Surg, V14, P343
[67]   Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin [J].
Woodburn, KW ;
Fan, Q ;
Kessel, D ;
Luo, Y ;
Young, SW .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (05) :746-751
[68]   Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model [J].
Woodburn, KW ;
Fan, Q ;
Miles, DR ;
Kessel, D ;
Luo, Y ;
Young, SW .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1997, 65 (03) :410-415
[69]   Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer [J].
Young, SW ;
Woodburn, KW ;
Wright, M ;
Mody, TD ;
Fan, Q ;
Sessler, JL ;
Dow, WC ;
Miller, RA .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1996, 63 (06) :892-897
[70]   APOPTOSIS DURING PHOTODYNAMIC THERAPY-INDUCED ABLATION OF RIF-1 TUMORS IN C3H MICE - ELECTRON-MICROSCOPIC, HISTOPATHOLOGIC AND BIOCHEMICAL-EVIDENCE [J].
ZAIDI, SIA ;
OLEINICK, NL ;
ZAIM, MT ;
MUKHTAR, H .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1993, 58 (06) :771-776